Wharton’s jelly mesenchymal stem cells: a concise review of their secretome and prospective clinical applications
Frontiers in Cell and Developmental Biology · 27.06.2023 · 11
DOI: 10.3389/fcell.2023.1211217 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 27.06.2023. Verfasst von Hana Drobiova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Human Genetics Unit, Department of Pathology, College of Medicine, Kuwait University, Jabriya, Kuwait. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 288 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kuwait Foundation for the Advancement of Sciences.
Abstract (Originalsprache)
Accumulating evidence indicates that most primary Wharton’s jelly mesenchymal stem cells (WJ-MSCs) therapeutic potential is due to their paracrine activity, i.e., their ability to modulate their microenvironment by releasing bioactive molecules and factors collectively known as secretome. These bioactive molecules and factors can either be released directly into the surrounding microenvironment or can be embedded within the membrane-bound extracellular bioactive nano-sized (usually 30–150 nm) messenger particles or vesicles of endosomal origin with specific route of biogenesis, known as exosomes or carried by relatively larger particles (100 nm–1 μm) formed by outward blebbing of plasma membrane called microvesicles (MVs); exosomes and MVs are collectively known as extracellular vesicles (EVs). The bioactive molecules and factors found in secretome are of various types, including cytokines, chemokines, cytoskeletal proteins, integrins, growth factors, angiogenic mediators, hormones, metabolites, and regulatory nucleic acid molecules. As expected, the secretome performs different biological functions, such as immunomodulation, tissue replenishment, cellular homeostasis, besides possessing anti-inflammatory and anti-fibrotic effects. This review highlights the current advances in research on the WJ-MSCs’ secretome and its prospective clinical applications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Human Genetics Unit, Department of Pathology, College of Medicine, Kuwait University, Jabriya, Kuwait.
- Animal and Imaging Core Facilities, Dasman Diabetes Institute, Dasman, Kuwait.
- Department of Immunology and Microbiology, Dasman Diabetes Institute, Dasman, Kuwait.
- Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Dasman, Kuwait.
Förderung
- Kuwait Foundation for the Advancement of Sciences
Zitieren
APA
Drobiova, H., Sindhu, S., Ahmad, R., Haddad, D., Al-Mulla, F., & Al Madhoun, A. (2023). Wharton’s jelly mesenchymal stem cells: a concise review of their secretome and prospective clinical applications. Frontiers in Cell and Developmental Biology, 11. https://doi.org/10.3389/fcell.2023.1211217
Vancouver
Drobiova H, Sindhu S, Ahmad R, Haddad D, Al-Mulla F, Al Madhoun A. Wharton’s jelly mesenchymal stem cells: a concise review of their secretome and prospective clinical applications. Frontiers in Cell and Developmental Biology. 2023;11. doi:10.3389/fcell.2023.1211217
BibTeX
@article{Drobiova2023,
author = {Drobiova, Hana and Sindhu, Sardar and Ahmad, Rasheed and Haddad, Dania and Al-Mulla, Fahd and Al Madhoun, Ashraf},
title = {Wharton’s jelly mesenchymal stem cells: a concise review of their secretome and prospective clinical applications},
journal = {Frontiers in Cell and Developmental Biology},
year = {2023},
volume = {11},
doi = {10.3389/fcell.2023.1211217}
}
EUVIMED